The DOI matches its Crossref record.
Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Abstract
KRASG12D is the most frequent KRAS mutation in human cancers, with the highest prevalence in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). RMC-9805 is a first-in-class, oral, mutant-selective covalent inhibitor of the GTP-bound and active RAS(ON) form of KRASG12D. The formation of a stable, high affinity tri-complex between RMC-9805, KRASG12D and cyclophilin A results in the suppression of signaling downstream of KRASG12D(ON) by disrupting its interactions with downstream effectors such as RAF kinases. RMC-9805 treatment caused selective and persistent modification of KRASG12D leading to deep and durable suppression of RAS pathway activity, inhibition of cell proliferation, and apoptosis induction in KRASG12D human cancer cell lines in vitro and tumor models in vivo. In a mouse clinical trial with KRASG12D xenograft tumor models, RMC-9805 administered orally as a single agent was well tolerated and induced objective responses in 7 of 9 PDAC PDX and CDX models and 6 of 9 NSCLC PDX models, as assessed by mRECIST. In the few models that exhibited sub-optimal responses to RMC-9805 monotherapy, combination treatment with various RAS Companion Inhibitors improved depth and/or duration of anti-tumor response. In contrast to RASMUTANT NSCLC and PDAC, CRC tumors are less dependent on RAS driver mutations. For example, a more heterogeneous response to KRASG12C inhibitors has been reported in CRC than in NSCLC patients, suggesti…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other inhibitors, including RMC-9805, 6 TH-Z835, 7 and BI2852, 8 have also been identified.”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [6]
Citations
Cites
Still being checked.
Cited by
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Zhou, C., Li, C., Luo, L., Li, X., Jia, K., He, N., Mao, S., Wang, W., Shao, C., Liu, X., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.001 · Cited by 102
Self-citationMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
Metadata
- Authors
- Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., Chin, S., Chou, K.-J., Mu, Y., Longhi, M., McDowell, L., Knox, J. E., Gill, A., Smith, J. A., Singh, M., Quintana, E., & Jiang, J.
- Affiliations
- Revolution Medicines (United States) (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2023-04-04
- Volume
- 83
- Issue
- 7_Supplement
- Pages
- 526-526
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4362536215
- Cited by
- 76
- References
- 0
- Citations by year
- 2026: 16 · 2025: 38 · 2024: 19 · 2023: 3
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12D inhibitors, covalent KRAS inhibitor, mutant-selective inhibitors, cyclophilin A, Ras signaling, pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer, apoptosis, combination therapy, resistance, oral anticancer drugs, xenograft models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers. https://app.cochat.ai/papers/10.1158/1538-7445.am2023-526
- The paper
- Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., Chin, S., Chou, K.-J., Mu, Y., Longhi, M., McDowell, L., Knox, J. E., Gill, A., Smith, J. A., Singh, M., . . . Jiang, J. (2023). Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers. Cancer Research. https://doi.org/10.1158/1538-7445.am2023-526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.